Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins

By Sandip Ray, Markus Britschgi, C. Herbert, Yoshiko Takeda-Uchimura, A. Boxer, Kaj Blennow, Leah F Friedman, D. Galasko, M. Jutel, A. Karydas and 15 more. Nature Medicine, 2007

1,096 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/6ae18fd486195a992b9508a4392c5e8a880ba0a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

1. J. Götz
2. L. Ittner
3. John Hardy
4. Kaj Blennow
5. D. Holtzman
6. Richard Frank
7. L. Fass

In Molecular Biology

1. D. Holtzman
2. John Hardy
3. L. Ittner
4. J. Götz
5. T. Wyss‐Coray
6. Claudio Franceschi
7. Henrik Zetterberg
8. Harald Hampel

In Physiology

1. D. Holtzman
2. Henrik Zetterberg
3. Kaj Blennow
4. John Hardy
5. J. Rogers
6. Harald Hampel
7. S. Rivest
8. L. Ittner

Citations in the corpus

• Animal models of Alzheimer's disease and frontotemporal dementia (2008, background): “The analyzed material includes human brain, cerebrospinal fluid (CSF) and plasma, as well as tissue culture cells and brain and spinal cord tissue from animal model”
• Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. (2017, background): “These have been found associated with cognitive impairment and AD pathology (Leung et al., 2013; Ray et al., 2007; Soares et al., 2012a; Doecke et al., 2012; Chen et al., 2015; Tan et al., 2013).”
• Immune activation in brain aging and neurodegeneration: too much or too little? (2009, background): “Similarly, changes in patterns of soluble immune mediators and other communication factors in the periphery have been linked to AD, HD, and PD and were used to predict disease progression (Bjorkqvist et al., 2008; Ray et al., 2007; Scherzer et al., 2007).”
• Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. (2012, background): “Cytokine or chemokine changes in the brain parenchyma are frequently accompanied by parallel changes in protein levels in the CSF, and some of these proteins appear to be dysregulated in the periphery as well (Ray et al. 2007; Zhang et al. 2008; Soares et al. 2009; Hu et al. 2010b).”
• Regulation of innate immune responses in the brain (2009, background): “In this regard, low levels of macrophage colony-stimulating factor ( M-CSF ; also known as CSF1) were recently found in patients with presymptomatic Alzheimer's disease or mild cognitive impairment, which together with low levels of other haematopoietic cytokines predicted the rapid development of t”
• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010, positive): “Nevertheless, a recent pilot study reported diagnostically useful patterns of 18 different signalling, acute phase and inflammatory proteins in plasma that warrant further investigatio”
• Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of β-secretase (2008, background): “BACE1 -AS may have utility as a new biomarker of Alzheimer's diseas”
• Multi-modal techniques for diagnosis and prognosis of Alzheimer’s disease (2009, background): “Other recent work, measuring 120 signalling proteins in plasma, suggested that sporadic Alzheimer's disease may be accompanied — and diagnosed in its very early stages — by a systemic inflammatory state characterized by a panel of 18 signalling molecule”
• Alzheimer’s Disease and the β-Amyloid Peptide (2010, neutral): “very difficult to sort out and remains an area of intense investigation [79].”
• Inflammaging and 'Garb-aging'. (2017, background): “12 are collectively indicated as “communicome” (see Box 4) [73].”